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Melanogenesis-related proteins play important roles in
melanin synthesis and antigenicity of melanomas. Identi-
fication of highly expressed melanoma-associated
antigens (MAA) that are immunogenic in humans will
provide potential targets for cancer vaccines. Melano-
genesis-related proteins have been shown to be MAA.
Autoantibody responses to these MAA have been shown
to react with melanoma cells and melanocytes, and
suggested to play a role in controlling melanoma progres-
sion. To assess antibody responses to potential
melanoma/melanocyte autoantigens, the open-reading
frame sequences of tyrosinase, tyrosinase-related protein
(TRP)-1, TRP-2, and melanoma-associated glycoprotein
antigen family (gp100/pmel17) genes were cloned and
expressed as recombinant proteins in E. coli. Purified
recombinant antigens were employed to detect antibodies
in sera of melanoma patients and normal healthy donors.
One of the major inherent characteristics of melanocytesand melanoma cells is the expression of the melano-genesis-related proteins (Orlow et al, 1995; del Mar-mol and Beermann, 1996). The major melanogenesis-related proteins that have been cloned and character-
ized are tyrosinase, tyrosinase-related protein (TRP)-1, TRP-2, and
melanoma-associated glycoprotein antigen family (gp100/pmel17) (del
Marmol and Beerman, 1996; Jackson, 1988; Kwon et al, 1991;
Tsukamoto et al, 1992; Kwon, 1993; Adema et al, 1994; Kobayashi
et al, 1994). The functional enzyme activity of tyrosinase, TRP-1, and
TRP-2 in production of melanin has been described in the Mason-
Raper melanogenesis pathway (Kwon, 1993). These three enzymes
have been shown to have µ40% amino acid homology to each other.
The role of gp100/pmel17 in the melanogenesis pathway is not known
but has been associated with the filamentous matrix of melanosomes
(Kwon et al, 1991; Adema et al, 1994). Gp100 gene has been shown
to be highly related to the pmel17 gene family. The difference between
these two genes is the in-frame deletion of a 21 base pair sequence in
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By affinity enzyme-linked immunosorbent assay and
western blotting, all recombinant antigens were shown
to be antigenic. The main subclass of antibody response
to these antigens was IgG. Most importantly this study
demonstrated anti-TRP-2 and anti-gp100/pmel17 IgG
responses in melanoma patients. Only one of 23 normal
donors had an antibody response to the antigens tested.
MAA-specific IgG antibodies in sera were assessed in
melanoma patients (n J 23) pre- and post-polyvalent
melanoma cell vaccine treatment. Polyvalent melanoma
cell vaccine treatment enhanced anti-MAA antibody
responses; however, only anti-TRP-2 and anti-gp100/
pmel17 antibody response was enhanced. These studies
suggest that four melanogenesis-related proteins are auto-
immunogenic and can be used as potential targets for
active-specific immunotherapy. Key words: autoimmunity/
gp100/TRP-2/vaccine. J Invest Dermatol 111:662–667, 1998
gp100 (Adema et al, 1994). In this study we will refer to gp100 and
pmel17 as one antigen (gp100/pmel17). The melanogenesis-related
proteins are consistently expressed in most melanoma tissue biopsies
and melanocytes (Sarantou et al, 1997). Several of the proteins
have been of major interest because of their roles in differentiation,
pigmentation, and antigenicity (Orlow et al, 1995; del Marmol and
Beermann, 1996). Color coating in the murine system has been
correlated to specific gene loci (Orlow et al, 1995). These gene loci
have been suggested to be related to the human melanogenesis-related
proteins: tyrosinase, albino locus; gp100/pmel17, silver locus; TRP-1,
brown locus; and TRP-2, slaty locus (del Marmol and Beerman, 1996).
Tyrosinase, TRP-1, and gp100/pmel17 have all been demonstrated
to be antigenic in humans (Mattes et al, 1983; Bakker et al, 1994; Song
et al, 1994; Baharav et al, 1995; Spagnoli et al, 1995; Naftzger et al,
1996). The antigenicity of these melanogenesis-related proteins has led
investigators to utilize them as target antigens in human cancer
vaccines. Because these melanogenesis-related proteins are autoantigens,
‘‘educating’’ the host immune system to convert from a potential state
of immune tolerance or suppression to an effective anti-melanoma
immune response has been a major task. Human leukocyte antigen
restricted cytotoxic T lymphocyte (CTL) responses have been reprodu-
cibly demonstrated with tyrosinase and gp100/pmel17 peptides in
melanoma patients by several groups (Bakker et al, 1994; Brichard et al,
1993; Spagnoli et al, 1995). Recently CTL have been shown to
recognize peptides of TRP-1 and TRP-2 (Wang et al, 1995, 1996).
Vitiligo is a depigmenting skin disease in which melanocytes of the
epidermis are destroyed (Cui et al, 1992; Song et al, 1994). The disease
occurs in various degrees from small depigmented patches of skin to
very large areas of the body. Although there has been strong linkage
of the presence of anti-melanocyte antigen antibodies in vitiligo
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patients, the etiology of the disease is still uncertain. Autoantibody
responses to tyrosinase, TRP-1, and TRP-2 have been demonstrated
in vitiligo patients’ sera (Mattes et al, 1983; Song et al, 1994; Baharav
et al, 1995; Kemp et al, 1997). TRP-1, originally defined as gp75, was
identified and well characterized using melanoma patients’ sera (Mattes
et al, 1983; Vijayasaradhi et al, 1990). No major studies on autoantibody
responses to gp100/pmel17 or TRP-2 proteins in comparing melanoma
and vitiligo patients’ sera have been demonstrated to date. Evaluation of
immune responses to melanoma/melanocyte autoantigens in melanoma
patients is important in determining their roles in tumor progression
and as potential target antigens in active-specific immunotherapy.
Melanoma-associated hypopigmentation, a clinical observation similar
to vitiligo, is observed in melanoma patients (Merimsky et al, 1996).
The relation between the functional role of melanoma/melanocyte
autoimmunity to that of controlling melanoma progression remains to
be determined. Although there have been studies on immune responses
to individual melanoma/melanocyte autoantigens, there have not been
any major melanogenesis-related studies assessing multiple autoantigens
in the same patient.
Antibody responses to melanoma-associated antigens (MAA) are
suggested to play an important role in controlling melanoma progression
(Jones et al, 1981; Bystryn et al, 1992; Morton et al, 1992; Livingston
et al, 1994; Mittelman et al, 1994; Naftzger et al, 1996). In recent years,
emphasis of analysis of MAA has been on CTL studies; however,
studies on antibody responses in humans are limited. This is primarily
due to the limited availability of purified native or recombinant whole
MAA protein. Recently, we have demonstrated antibody responses to
the melanoma antigen (MAGE)-1 using purified recombinant protein
(Hoon et al, 1995b). The availability of recombinant MAA proteins
provides a useful tool in assessing antibody responses to the whole
antigen in patients. This analysis is particularly useful when the specific
antigenic epitope on the MAA is not known, or when there are
multiple antigenic epitopes. Isolation of natural occurring melanoma
proteins from melanoma specimens is very laborious and logistically
unpractical for routine assay analysis. To assess melanoma/melanocyte
autoantigen antibody responses in melanoma patients, we cloned,
expressed, and purified recombinant proteins of tyrosinase, TRP-1,
TRP-2, and gp100/pmel17 in E. coli, and developed MAA-specific
enzyme-linked immunosorbent assay (ELISA).
MATERIALS AND METHODS
Patients and sera collection Sera were collected from healthy volunteer
donors and melanoma patients. Polyvalent melanoma cell vaccine (PMCV)
treated patients had not received any immunotherapy, chemotherapy, or
radiotherapy within 30 d prior to the start of the PMCV treatment. None of
the patients had received immunotherapy anytime prior to PMCV treatment.
Melanoma patients’ blood was drawn prior to PMCV treatment (day 0).
Melanoma patients were treated with PMCV consisting of three well-defined
allogeneic melanoma cell lines as previously described (Morton et al, 1992;
Hoon et al, 1995b). Briefly, patients were given PMCV on day 0, weeks 2, 4,
8, 12, and 16, and then every 3–6 mo. Post-PMCV blood was collected from
patients after 4–5 PMCV treatments (weeks 12–16). This time point during
PMCV has previously been shown to be the optimal point for assessment of
anti-protein MAA responses if they are going to occur and be elevated from
pre-PMCV (Morton et al, 1992). Patients underwent routine clinical evaluation
for recurrence of disease during this time period. Melanoma patients in the
study were selected on the basis of sera availability and by the following criteria:
American Joint Committee on Cancer (AJCC) stage III disease with no clinical
evidence of disease (NED) at the start of PMCV and after 4–5 treatments.
These patients survived five or more years after PMCV treatment and had no
evidence of disease recurrence. Because clinical disease progression can affect
antibody responses and the state of immune responses, we selected patients
who were disease-free with favorable responses to PMCV. Blood was collected
and centrifuged, and serum aliquoted and cryopreserved at 230°C until assayed
as previously described (Hoon et al, 1995b).
Expression vectors of MAA recombinant proteins Total RNA was
prepared from the established melanoma cell line M12, and reverse transcribed
into cDNA as described previously (Hoon et al, 1995a; Doi et al, 1996). The
cDNA of tyrosinase (1356 bp), TRP-1 (1509 bp), TRP-2 (1356 bp), and
gp100/pmel17 (1899 bp) were amplified by polymerase chain reaction. Oligo-
nucleotides used to amplify the genes of tyrosinase, TRP-1, TRP-2, and gp100
were synthesized based on GenBank sequences. The primer sets for individual
MAA were synthesized as follows: Tyrosinase, 59-AGCTGGATCCGCCTGT-
GTCTCCTCTAAGAACC-39 and 59-ATGCCTCGAGGATCCGACTCG-
CTTGTTCCA-39; TRP-1, 59-GGTTGAGCTCACAATTCCCAAGACAG-
TGTGCC-39 and 59-CCTTCTCGAGTATTCTTTCTTCAGCATAGCA-39;
TRP-2, 59-AGCTGGATCCCAGGGTCAGTTCCCCCGAGTC-39 and
59-ATGCCTCGAGCTCTCAACACCCGGTTGGACC-39; gp100/pmel17,
59-GTGAGAGCTCATTGGCTGTGATAGGTGCTT-39 and 59-CAAACT
CGAGGAAGATGCGGGGTAGACG-39. The 59 primers include BamHI
(tyrosinase and TRP-2) or SacI restriction site (TRP-1 and gp100) and the 39
primers contain XhoI restriction site for cloning into the expression vector.
Then the cDNA of the MAA were digested with respective restriction enzymes
and cloned into an expression vector pGEX/HIS, allowing the expression of
GST fusion protein with a C-terminal 6xHis affinity tag after induction. The
pGEX/HIS vector was reengineered from the pGEX-2T vector (Pharmacia,
Piscataway, NJ) by inserting into the SmaI site a DNA fragment containing
multiple cloning sites followed by a 6xHis tag.
Expression and purification of recombinant proteins The protein expres-
sion plasmids were transformed into E. coli strain BL21 or DH5α cells.
Recombinant fusion proteins were induced by isopropyl-D-thiogalactoside and
purified from bacterial lysates by affinity chromatography using Glutathione
Sepharose 4B (Pharmacia, Piscataway, NJ). The GST fusion proteins of MAA
were first bound to the affinity column and the recombinant proteins tyrosinase,
TRP-1, TRP-2, and gp100/pmel17 were cleaved from the GST carrier by
thrombin and then eluted from the column. The affinity purified recombinant
proteins were further purified by preparative sodium dodecyl sulfate gel
electrophoresis using a Model 491 Prep Cell (Bio-Rad, Hercules, CA) or
through an anion exchange ‘‘Q’’ column using the Bio-Rad FPLC system
according to the manufacturer’s instructions.
Western blotting analysis of recombinant MAA proteins Recombinant
MAA proteins purified by affinity column (Glutathione Sepharose 4B) followed
by cleavage with thrombin were applied to sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis and electroblotted on to Hybond ECL nitrocellulose
membrane (Amersham, Chicago, IL). For the detection of polyhistidine tag,
the blot was blocked by 5% blocking reagent (Amersham) in phosphate-buffered
saline (PBS)-0.05% Tween followed by incubation with 1: 500 dilution anti-
His6-peroxidase (Boehringer, Indianapolis, IN) in PBS-Tween. The blot was
developed by ECL western blotting detection reagent (Amersham) following
the manufacturers’ protocol. For the detection of tyrosinase, the blot was
blocked by 2.5% bovine serum albumin (Sigma, St Louis, MO) in PBS-0.05%
Tween followed by incubation with 1:200 dilution in PBS at room temperature
for an hour. After washing three times with PBS-Tween, the blot was incubated
with 1:200 anti-tyrosinase mouse monoclonal antibody (Vector Laboratories,
Burlingame, CA) in PBS at room temperature for an hour. After washing with
PBS-Tween, the blot was incubated with 1:1000 dilution of alkaline phosphatase-
conjugated goat anti-mouse IgG (γ-chain specific) (Boehringer) and then
developed using 5-bromo-4-chloro-3-indolyl-1-phosphate and nitroblue tetra-
zolium (Promega, Madison, WI) according to the manufacturer’s procedure.
Reverse transcriptase-polymerase chain reaction (RT-PCR) of PMCV
cell lines PMCV cell lines A, B, and C, and melanoma cell line M12, were
established and characterized at the JWCI as previously described (Morton et al,
1992; Sarantou et al, 1997). RNA preparation, the RT-PCR assay, and the
oligonucleotide primers of tyrosinase, TRP-1, TRP-2, and gp100/pmel 17
used in the RT-PCR assay were performed as previously described (Doi et al,
1996; Sarantou et al, 1997). Porphobilinogen deaminase was used as a control
housekeeping gene in the RT-PCR reaction. Equal amounts (0.5 µg) of RNA
were used for each reaction.
Affinity ELISA Affinity ELISA with purified recombinant proteins tyrosinase,
TRP-1, TRP-2, and gp100/pmel17 containing a 6xHis tag was performed as
previously described (Okamoto et al, 1997). Recombinant proteins were
incubated overnight at room temperature in Ni21 chelate-coated ELISA
microwell plates (Xenopore, Hawthorne, NJ) according to the manufacturer’s
procedure. Sera were added in 2-fold dilution with PBS from 1:40 to 1:1280
and incubated at room temperature for 2 h in duplicate. Goat anti-human γ-
chain or human µ-chain antibody conjugates (Boehringer) were used for
detection of human IgG or IgM specific antibodies, respectively. ELISA were
developed and read using a Molecular Device ELISA reader and analyzed using
software provided by the manufacturer (San Francisco, CA). Antibody titers
were defined as the highest serum dilution yielding absorbency reading greater
than the mean plus two standard deviations above normal donor volunteer
serum background absorbance at 1:40 dilution. Although 1:1280 serum dilution
was tested, no patient was positive for this titer.
Western blotting Western blotting was performed as previously described
(Hoon et al, 1995b). Recombinant proteins were run on sodium dodecyl
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sulfate-polyacrylamide gel electrophoresis and blotted. Patients’ sera were diluted
in PBS buffer, followed by incubation with 1:1000 dilution of alkaline
phosphatase-conjugated anti-human IgG (γ-chain specific) or anti-human IgM
(µ-chain specific) (Boehringer) and then developed by using 5-bromo-4-chloro-
3-indolyl-1-phosphate and nitroblue tetrazolium (Promega) according to the
manufacturer’s procedure.
Statistical analysis Assessment of antibody responses between patients and
normal donors was carried out using Wilcoxon rank test. Analysis of antibody
responses pre-PMCV immunization versus post-PMCV immunization was
carried out using a generalized McNemar test (Fleiss, 1981).
RESULTS
Cloning, expression, and purification of MAA recombinant
proteins The MAA tyrosinase, TRP-1, TRP-2, and gp100/pmel17
genes open-reading frame were successfully cloned, expressed, and
purified. The amplified cDNA of tyrosinase (1356 bp) and cDNA of
TRP-2 (1356 bp) both code for N-terminal 452 amino acid proteins.
The amplified cDNA of TRP-1 (1509 bp) code for the full-length
protein 503 amino acids, and cDNA of gp100/pmel17 (1899 bp) code
for the protein 633 amino acids. The cDNA products were subcloned
into specific sites of the expression vector pGEX/HIS. The vector
pGEX/HIS, containing multiple cloning sites flanked by GST gene at
the 59-end and 6xHis tag at the 39-end, was constructed by replacing
the SmaI site of pGEX-2T with a blunt-ended EcoR V-Blp I fragment
from pET-30b(1) vector (Novagen, Madison, WI). Therefore, induc-
tion of the transformed clones by isopropyl-D-thiogalactoside resulted
in the expression of a GST fusion protein with the 6xHis tag at the
C-terminus. The expression of recombinant fusion proteins of the
MAA was verified by western blot analysis by both anti-GST antibody
and Ni21 -NTA conjugate antibody.
The four recombinant GST fusion MAA proteins were purified by
GST affinity column chromatography, and the MAA alone were
cleaved from the GST peptide by thrombin protease and then eluted
from the column. Western blotting analysis of the individual recombin-
ant MAAs with 6xHis tag was detected using anti-polyhistidine antibody
(Fig 1A). Both recombinant tyrosinase and TRP-2 have a molecular
mass of 54 kDa, which was similar to the predicted molecular mass of
the translation product (estimated 53 kDa). Recombinant TRP-1 has
a molecular mass of 63 kDa, which was slightly larger than the estimated
molecular mass of 59 kDa. Gp100/pmel17 was 67 kDa on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis analysis, which was
close to the estimated molecular mass (69 kDa). Differences in
recombinant protein size as determined by gel electrophoresis compared
with the predicted size is often observed (Hoon et al, 1995b). This
difference by gel analysis can be due to protein charge, overall amino
acid composition, and/or migration ability in the gel. Different
preparations and purifications of the individual recombinant MAA
showed similar sizes.
To further verify the validity of the recombinant MAA, anti-
tyrosinase antibody was assessed in western blot analysis against the
four MAA (Fig 1B). Only tyrosinase protein reacted with the antibody
at the molecular weight shown by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis analysis.
MAA mRNA expression by PMCV lines The PMCV cell lines
were assessed by RT-PCR for the expression of MAA (Fig 2). Normal
melanocytes expressed all the MAA markers, and in general these
MAA are frequently (.75%) expressed in primary and metastatic
melanoma biopsies (Sarantou et al, 1997). All PMCV cell lines were
RT-PCR positive for all MAA markers. As positive controls, we
assessed individual MAA plasmid DNA (tyrosinase, TRP-1, TRP-2,
and gp100/pmel17). The melanoma cell line M12 used to clone the
MAA genes was shown to express all MAA by RT-PCR analysis.
Western blot analysis of anti-MAA responses Initial screening
of melanoma patients antibody responses to MAA was performed by
western blotting. Sera from melanoma patients and normal volunteer
donors were assessed at various dilutions. Representative western blot
analysis of anti-tyrosinase, TRP-1, TRP-2, and gp100/pmel17 IgG
antibody responses are shown in Fig 3. Normal donors showed no
Figure 1. Western blotting analysis of recombinant MAA proteins
detected by (A) anti-polyhistidine monoclonal antibody and (B) anti-
tyrosinase antibody. All MAA were blotted on to the membranes in
equal amounts.
MAA-specific IgG or IgM responses. Analysis of IgM responses to the
individual MAA were very weak or absent in melanoma patients.
Western blot analysis demonstrated antibody specific binding to the
purified recombinant MAA. A control protein (HOJ-1 with a 6xHis
tag) expressed as an E. coli recombinant fusion protein and purified in
a similar manner as the MAA showed no antibody reactivity in western
blots. Patients were also assessed for anti-MAGE-3 antibodies using
MAGE-3 recombinant protein. MAGE-3 protein was purified in a
similar manner to the other recombinant MAA. Anti-MAGE-3 IgG
and IgM antibodies were found infrequently at low antibody dilutions
(data not shown). This indicated that the binding of antibody to the
melanogenesis autoantigens was not due to an expression induced
artifact, nor a result of E. coli bacterial components potentially carried
during the purification of the recombinant proteins nor due to reactivity
to 6xHis tag. Differential antibody response to individual MAA
from the same patients also indicated the responses were specific to
the antigens.
Anti-MAA responses in melanoma patients and healthy normal
donors An anti-MAA affinity ELISA was developed to assess melan-
oma patients’ IgG responses. Recombinant protein with a 6xHis tag
was coated on Ni21 chelate-coated ELISA microwell plates. In previous
studies by our laboratory and others, affinity ELISA using tagged
recombinant proteins was more consistent and sensitive than conven-
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Figure 2. RT-PCR analysis of PMCV lines for expression of tyrosinase,
TRP-1, TRP-2, and gp100/pmel17 mRNA. Lanes 1–5 represent H2O
control, PMCV line A, PMCV line B, PMCV line C, and M12 control
melanoma cell line, respectively. Lane 3 (PMCV line B) for TRP-2 has a weak
positive band not visible. Lane M refers to the base pair ladder as a reference.
Figure 3. Representative western blot analysis of melanoma patient
sera against recombinant tyrosinase, TRP-1, TRP-2, and gp100/pmel17
proteins. Representative examples of normal donor (lane 1) and four individual
patients’ (lanes 2–5) sera at a dilution 1:100 are shown.
tional protein adsorption ELISA (Okamoto et al, 1997). In this study
only IgG were evaluated because western blot analysis of patients’ sera
to recombinant MAA had very weak or no IgM responses. Melanoma
patients who were AJCC stage III NED and received PMCV were
followed up for more than 5 y in the study. Selecting patients with a
uniform, defined clinical status and equivalent follow-up was essential
in evaluating immune responses to the recombinant autoantigens. The
uniformity of patients’ clinical status is very important in interpreting
therapeutic efficacy of treatment protocols and also in the evaluation
of antigen-specific immune responses in patients. Often, the latter
criteria are ignored in immunologic assessments. Also, it was important
that patients had no previous immunotherapy prior to the start of the
PMCV therapy. This screening process is critical because both tumor
burden and other treatment can potentially affect immune responses
to MAA.
In comparing normal healthy donors versus pre-PMCV melanoma
patients, significantly higher IgG responses were observed for all four
MAA in the latter group (Table I). Only one normal donor had an
antibody response (1:40) to three of the MAA. Normal donors and
patients were matched on the basis of age and sex. This minimized
any potential bias in normal versus patient comparisons. Antibody titers
were measured in the range of 1:40–1:640 dilutions. The highest
antibody titer was observed at 1:640 for TRP-2 and at 1:320 for
tyrosinase, TRP-1, and TRP-2. The majority of the patients’ anti-
MAA antibody titers were clustered around 1:40 and 1:80. Assessment
of antibody responses in nontreated patients showed overall similar
results for individual patients. Non-treated patients with .1:40 antibody
dilution against individual MAA were observed in nine of 23 (39%)
patients against tyrosinase and five of 23 (22%) patients for the other
three MAA (Table I). Patients’ IgG titers (high and low responders)
to individual MAA did not correlate to patients’ human leukocyte
antigen class I phenotype (data not shown).
Anti-MAA IgG responses after PMCV treatment Twenty-three
melanoma patients (AJCC stage III, NED) who had received 4–5
PMCV treatments were evaluated for anti-MAA IgG responses. Two
of the PMCV cell lines were positive using anti-gp100 murine
monoclonal antibody (HMB-45) staining by flow cytometry. In Fig 4
anti-MAA IgG titers pre- and post-PMCV immunization are shown.
Patients were assessed at week 12–16 post-immunization (4–5 PMCV
treatments). This period is based on observation of optimal antibody
responses to other previously studied MAA in a PMCV-treated patient
(Morton et al, 1992). Several of the positive patients’ sera pre- and
post-immunization were verified for anti-MAA specificity by western
blotting to the individual MAA.
Enhancement of anti-MAA antibody responses after PMCV treat-
ment was observed in patients (Table I). The most significant enhance-
ment in antibody response post-immunization was observed against
TRP-2 (p 5 0.01) and gp100/pmel17 (p 5 0.016) (Table I, Fig 4c,
d). Comparison of pre- versus post-PMCV anti-Trp-2 responses in
seven patients showed an increase in titer. The post-PMCV analysis of
anti-gp100/pme117 IgG responses showed an increase in titer in six
patients. Enhancement of post-PMCV anti-tryosinase and anti-TRP-
1 IgG responses were detected in four and three patients, respectively;
however, no significant changes were observed in comparing pre-
versus post-PMCV treatment for both MAA responses. In assessing
patients with .1:40 titer post-immunization, anti-tyrosinase, and anti-
Trp-2 was observed in 10 of 23 patients (44%), anti-gp100/pme117 in
eight of 23 patients (35%), and anti-TRP-1 in four of 23 (17%) patients.
DISCUSSION
In this study we set out to examine antibody responses to melanogenesis
MAA in normal healthy donors and melanoma patients. Using western
blot analysis with recombinant MAA we demonstrated anti-MAA IgG
antibody responses in melanoma patients. One of the novel features of
the study was the demonstration of the immunogenicity of individual
MAA and, in particular, TRP-2 in humans. All the MAA except
TRP-2 have been demonstrated to be immunogenic in humans by
either antibody or CTL assays. It is somewhat surprising that the major
known enzymes in the melanogenesis pathway are all immunogenic
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Table I. Anti-MAA IgG titers in normal donors and melanoma patients
Detection of anti-MAA at different dilutionsb
Anti-MAA IgG Source of seraa 1:40 1:80 1:160 1:320 1:640 Positive/total tested (%)
Tyrosinase Normal donors 1 0 0 0 0 1/23 (4)
Pre-PMCV 4 4 3 2 0 13/23 (57)
Post-PMCV 3 3 5 2 0 13/23 (57)
TRP-1 Normal donors 0 0 0 0 0 0/23 (0)
Pre-PMCV 5 4 1 0 0 10/23 (43)
Post-PMCV 5 2 1 1 0 9/23 (39)
TRP-2 Normal donors 1 0 0 0 0 1/23 (4)
Pre-PMCV 6 3 1 1 0 11/23 (48)
Post-PMCV 3 6 2 1 1 13/23 (57)
Gp100/pmel17 Normal donors 1 0 0 0 0 1/23 (4)
Pre-PMCV 6 3 2 0 0 11/23 (48)
Post-PMCV 5 5 3 0 0 13/23 (57)
aPre-PMCV sera was tested on day 0 of the first PMCV treatment. Post-PMCV sera were assessed after 12–16 wk of PMCV treatment.
bNormal donors versus pre-PMCV melanoma patients for anti-tyrosinase, anti-TRP-1, anti-TRP-2, anti-gp100/pmel17, were p , 0.0001, , 0.003, , 0.005, and , 0.005, respectively.
Figure 4. Assessment of PMCV-treated melanoma patients for induction
of anti-MAA IgG responses. In individual patients’ responses pre- and post-
PMCV treatment are shown. Each point represents the mean of duplicate assays.
in humans. All of the melanogenesis-related MAA studied in this report
are expressed in melanocytes (del Marmol and Beerman, 1996; Sarantou
et al, 1997). The four melanogenesis MAA studied are expressed in
greater than 75% of primary and metastatic melanoma biopsies from
individual patients as assessed by RT-PCR plus Southern blot analysis
(Sarantou et al, 1997). Antibody responses to all melanogenesis MAA
were observed in melanoma patients and not in normal donors, with
the exception of only one donor. Previously, TRP-1 and tyrosinase
have been demonstrated antigenic by assessment of melanoma patients’
sera (Mattes et al, 1983; Fishman et al, 1997).
Human TRP-2 gene was recently cloned and functionally identified
as the enzyme dopachrome tautomerase responsible for the conversion
of the dopachrome to 5,6-dihydroxyindole-2-carboxylic acid (Tsukam-
oto et al, 1992; Bouchard et al, 1994). TRP-2 has been demonstrated
to be more consistently present in melanotic or amelanotic melanomas;
however, no direct correlation of eumelanin to TRP-2 expression and
activity has been shown. We have demonstrated that TRP-2 mRNA
is found in primary and metastatic melanoma biopsies (Sarantou et al,
1997). Recently, a TRP-2-derived peptide has been shown to be
antigenic by recognition of human CTL (Wang et al, 1996). This study
suggested the potential antigenicity of the TRP-2 gene product. Our
analysis of TRP-2 protein in melanoma patients treated with active-
specific immunotherapy with TRP-2 (PMCV) indicates that TRP-2
is immunogenic in humans. TRP-2 may be potentially useful as an
immunogen similar to tyrosinase or gp100 in cancer vaccines. TRP-2
as well as TRP-1 have been identified to be intracellular proteins
primarily associated with melanosomes (del Marmol and Beerman,
1996). TRP-1 has been shown to be expressed on the cell surface of
melanomas (Takechi et al, 1996). Antibodies to other melanocyte
antigens have been demonstrated in the autoimmune disease vitiligo
but their specificities have not been well defined (Naughton et al,
1983; Cui et al, 1992).
Autoantibody responses to some of the individual melanogenesis
MAA were elevated in some patients in post-PMCV compared with
pre-PMCV sera. The anti-TRP-2 and gp100/pmel17 had the most
significant responses post-immunization. Gp100/pmel17 has been
shown to be very antigenic in humans, as demonstrated by CTL
induced to gp100/pme117-derived peptides (Bakker et al, 1994;
Spagnoli et al, 1995). The IgG response to gp100/pmel17 suggests that
a T helper2 response can also be induced. Currently, several cancer
vaccines have focused on melanogenesis-related MAA such as gp100/
pmel17 human leukocyte antigen-A2 motif peptides to induce T cell
responses in patients (Maeurer et al, 1996; Zhai et al, 1996). To date,
however, presence of anti-melanogenesis MAA T cell responses in
immunized patients have not consistently been correlated to significant
improved prognosis. Better strategies are needed in immunization and
delivery. If a strong IgG response to an antigen is induced there is a
potential for CTL or T helper1 responses to be suppressed. This
phenomenon has been referred to as ‘‘immune deviation’’ and docu-
mented for various in vivo antigen responses (Tuttosi and Bretscher,
1992). An immune deviation towards a particular type of response on
immunization may not always be efficacious. Studies need to be
designed to determine the significance of both antibody responses and
CTL responses to specific MAA in melanoma patients.
The significance of the antigenicity of the individual melanogenesis
MAA in melanoma patients is unknown. One of the most important
observations in this study is that PMCV can enhance or induce IgG
responses to melanogenesis MAA. Although the response did not occur
in all patients, there was an indication that patients could be induced
to produce higher titers to the individual melanogenesis MAA. The
native proteins of MAA may be more antigenic and produce a
higher anti-MAA response compared with denatured proteins. The
immunologic events relating to immune self-recognition of melanocytes
and melanoma rejection have been puzzling (Houghton, 1994). There
is strong suggestive evidence that the destruction of melanocytes in
vitiligo is due to autoantibody(s) against melanocytes that may be
similar to mechanisms involved in immune-related melanoma regression
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(Cui et al, 1992; Merimsky et al, 1996; Kawakami and Rosenberg,
1997). Several of the autoantibodies reactivities to specific melanocyte/
melanoma antigens are well defined, whilst others are not. Anti-
tyrosinase antibodies have been reported in vitiligo as well as melanoma
patients (Song et al, 1994; Merimsky et al, 1996; Fishman et al, 1997).
The immunologic responses to the specific melanogenesis-related
proteins in vitiligo and melanoma patients with tumor regression after
therapy have not been well studied. There is the possibility that the
anti-melanogenesis MAA response is a secondary immunologic event
as a consequence of the release of MAA after melanoma cell destruction
from other events. Vitiligo depigmentation has been observed in
several melanoma patients being treated with PMCV and in other
immunotherapy studies reported (Berd et al, 1996; Kwakami, 1997).
The availability of recombinant MAA will allow us in the future to
assess melanoma patients for antigen-specific antibody responses during
active-specific immunotherapy. The induction of antibody responses
in patients is an indicator that the immunization protocol is functional
in terms of immunogenicity. Although the role of autoantibodies to
melanogenesis MAA is not well understood in melanoma patients, they
may have some effector role. Studies have shown that autoantibodies to
intracellular proteins can be induced and can penetrate cells via Fc
receptors and by other mechanisms (Alarcon-Segovia et al, 1996). It is
becoming more evident that individual MAA proteins can elicit both
T cell and antibody responses; however, of the major MAA studied it
is still not known which MAA or type of immune response(s) (antibody
or T cell) is clinically relevant for effective control of malignant
melanoma. Future studies will involve assessment of both T and
antibody responses to individual melanogenesis MAA. The immuno-
genicity of anti-melanogenesis MAA IgG responses provides another
tool for the rapid assessment of immunogenicity of cancer vaccines
(whole cell, membrane lysate, or subunit) in patients.
We thank K. Qi for statistical analysis and the staff of JWCI. We also thank D. Yuzuki
and V. Chiang for their technical assistance.
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